KTTA and KTTAW Related Headlines
Go Back- Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
- Pasithea names Kartik Krishnan as chief medical officer
- Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
- Pasithea Therapeutics receives FDA rare pediatric disease designation for PAS-004
- Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
- Pasithea Therapeutics provides updated clinical trial timelines
- Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
KTTA and KTTAW Related Press Releases
Go Back- Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
- Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
- Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
- Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
